Research Papers:

LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome

Yi-Jun Hua, Hai-Yun Wang, Ling-Quan Tang, Qiu-Yan Chen, Jian-Yong Shao and Hai-Qiang Mai _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:8200-8207. https://doi.org/10.18632/oncotarget.6996

Metrics: PDF 1535 views  |   HTML 1774 views  |   ?  


Yi-Jun Hua1,2,*, Hai-Yun Wang1,3,*, Ling-Quan Tang1,2, Qiu-Yan Chen1,2, Jian-Yong Shao1,3, Hai-Qiang Mai1,2

1Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China

2Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

3Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

*These authors have contributed equally to this work

Correspondence to:

Jian-Yong Shao, e-mail: [email protected]

Hai-Qiang Mai, e-mail: [email protected]

Keywords: nasopharyngeal carcinoma, lysyl oxidase (LOX), expression, survival, prognosis

Received: September 15, 2015     Accepted: January 09, 2016     Published: January 23, 2016


Lysyl oxidase (LOX) is an extracellular matrix-remodeling enzyme that plays important roles in tumor development and progression. To evaluate the prognostic value of LOX levels in primary nasopharyngeal carcinoma, we performed an immunohistochemical analysis using 233 tissue biopsy specimens from as many patients. We found that the extent of immunohistochemical LOX staining correlated inversely with the clinicopathological features and survival. High LOX expression correlated with decreases in 5-year survival, overall survival, distant metastasis-free survival and disease-free survival (p < 0.05). Cox regression analysis confirmed that LOX was a significant prognostic indicator of increased risk of 5-year mortality for all patients (hazard ratio [HR], 1.670; 95% confidence interval [95% CI], 1.033–2.701 [p < .005]). Higher LOX expression was also an independent predictor of poor prognosis in patients with nasopharyngeal carcinoma. These findings suggest LOX may be a new biomarker predictive of NPC prognosis and may also be a useful treatment target.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6996